FDA Trims Broad Label for Biogen’s Alzheimer’s Drug Amidst Harsh Criticism
XTalks
JULY 12, 2021
We are committed to continue to listen to the community’s needs as clinical practice adapts to this important, first-in-class treatment option,” said Alfred Sandrock, Jr., On the other hand, Biogen is being aggressively questioned over its tacking on of such a hefty price tag for the drug.
98 
Let's personalize your content